Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Targeted molecular characterization shows differences between primary and secondary myelofibrosis.

Courtier F, Garnier S, Carbuccia N, Guille A, Adélaide J, Chaffanet M, Hirsch P, Luque Paz D, Slama B, Vey N, Ugo V, Delhommeau F, Rey J, Birnbaum D, Murati A.

Genes Chromosomes Cancer. 2019 Jul 24. doi: 10.1002/gcc.22789. [Epub ahead of print]

PMID:
31340059
2.

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.

Hoeks M, Yu G, Langemeijer S, Crouch S, de Swart L, Fenaux P, Symeonidis A, Čermák J, Hellström-Lindberg E, Sanz G, Stauder R, Holm MS, Mittelman M, Mądry K, Malcovati L, Tatic A, Almeida AM, Germing U, Savic A, Gredelj Šimec N, Culligan D, Itzykson R, Guerci-Bresler A, Slama B, van de Loosdrecht A, van Marrewijk C, Droste J, Blijlevens N, van Kraaij M, Bowen D, de Witte T, Smith A; EUMDS Registry Participants.

Haematologica. 2019 Jul 5. pii: haematol.2018.212332. doi: 10.3324/haematol.2018.212332. [Epub ahead of print]

3.

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Pertesi M, Vallée M, Wei X, Revuelta MV, Galia P, Demangel D, Oliver J, Foll M, Chen S, Perrial E, Garderet L, Corre J, Leleu X, Boyle EM, Decaux O, Rodon P, Kolb B, Slama B, Mineur P, Voog E, Le Bris C, Fontan J, Maigre M, Beaumont M, Azais I, Sobol H, Vignon M, Royer B, Perrot A, Fuzibet JG, Dorvaux V, Anglaret B, Cony-Makhoul P, Berthou C, Desquesnes F, Pegourie B, Leyvraz S, Mosser L, Frenkiel N, Augeul-Meunier K, Leduc I, Leyronnas C, Voillat L, Casassus P, Mathiot C, Cheron N, Paubelle E, Moreau P, Bignon YJ, Joly B, Bourquard P, Caillot D, Naman H, Rigaudeau S, Marit G, Macro M, Lambrecht I, Cliquennois M, Vincent L, Helias P, Avet-Loiseau H, Moreno V, Reis RM, Varkonyi J, Kruszewski M, Vangsted AJ, Jurczyszyn A, Zaucha JM, Sainz J, Krawczyk-Kulis M, Wątek M, Pelosini M, Iskierka-Jażdżewska E, Grząśko N, Martinez-Lopez J, Jerez A, Campa D, Buda G, Lesueur F, Dudziński M, García-Sanz R, Nagler A, Rymko M, Jamroziak K, Butrym A, Canzian F, Obazee O, Nilsson B, Klein RJ, Lipkin SM, McKay JD, Dumontet C.

Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0452-6. [Epub ahead of print] No abstract available.

PMID:
30967618
4.

Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.

Pegourie B, Karlin L, Benboubker L, Orsini-Piocelle F, Tiab M, Auger-Quittet S, Rodon P, Royer B, Leleu X, Bareau B, Cliquennois M, Fuzibet JG, Voog E, Belhadj-Merzoug K, Decaux O, Rey P, Slama B, Leyronnas C, Zarnitsky C, Boyle E, Bosson JL, Pernod G; IFM Group.

Am J Hematol. 2019 Jun;94(6):635-640. doi: 10.1002/ajh.25459. Epub 2019 Apr 1.

PMID:
30859608
5.

Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.

Chaoui D, Hacini M, Fitoussi O, Karlin L, Arkam Y, Jourdan E, Orfeuvre H, Voillat L, Sanhes L, Leprêtre S, Liu KL, Barry M, Tempescul A, Dilhuydy MS, Chaib A, Slama B, Labourey JL, Benbrahim O, Dreyfus B, Mahé B, Maynadié M, Delmer A, Benkanoun C, Boissard F, Gandon S, Veerabudun K, Choquet S; on behalf of the PERLE investigators .

Leuk Lymphoma. 2019 Jun;60(6):1563-1567. doi: 10.1080/10428194.2018.1533130. Epub 2019 Jan 9. No abstract available.

PMID:
30624147
6.

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.

Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M.

Haematologica. 2019 Mar;104(3):497-504. doi: 10.3324/haematol.2018.203158. Epub 2018 Oct 4.

7.

Erratum: Efficacy and safety of ClairYg®, a ready-to-use intravenous immunoglobulin, in adult patients with primary immune thrombocytopenia.

Slama B, Fain O, Maisonneuve H, Jourdan E, Viallard JF, Ouaja R, Alfa-Cissé O, Godeau B; Study Investigators.

Am J Blood Res. 2017 Jun 15;7(3):29. eCollection 2017.

8.

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.

Platzbecker U, Symeonidis A, Oliva EN, Goede JS, Delforge M, Mayer J, Slama B, Badre S, Gasal E, Mehta B, Franklin J.

Leukemia. 2017 Sep;31(9):1944-1950. doi: 10.1038/leu.2017.192. Epub 2017 Jun 19.

9.

Efficacy and safety of ClairYg®, a ready-to-use intravenous immunoglobulin, in adult patients with primary immune thrombocytopenia.

Slama B, Fain O, Maisonneuve H, Jourdan E, Viallard JF, Ouaja R, Alfa-Cissé O, Godeau B; Study Investigators.

Am J Blood Res. 2017 Jan 15;7(1):1-9. eCollection 2017. Erratum in: Am J Blood Res. 2017 Jun 15;7(3):29.

10.

Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial.

Viallard JF, Agape P, Barlogis V, Cozon G, Faure C, Fouyssac F, Gaud C, Gourin MP, Hamidou M, Hoarau C, Husseini F, Ojeda-Uribe M, Pavic M, Pellier I, Perlat A, Schleinitz N, Slama B.

BMC Immunol. 2016 Sep 29;17(1):34.

11.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, Puyade M, Escoffre M, Stoppa AM, Facon T, Pegourie B, Chaoui D, Jaccard A, Slama B, Marit G, Laribi K, Godmer P, Luycx O, Eisenmann JC, Allangba O, Dib M, Araujo C, Fontan J, Belhadj K, Wetterwald M, Dorvaux V, Fermand JP, Rodon P, Kolb B, Glaisner S, Malfuson JV, Lenain P, Biron L, Planche L, Caillon H, Avet-Loiseau H, Dejoie T, Attal M.

Blood. 2016 May 26;127(21):2569-74. doi: 10.1182/blood-2016-01-693580. Epub 2016 Mar 21.

12.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F.

Leukemia. 2016 Apr;30(4):897-905. doi: 10.1038/leu.2015.296. Epub 2015 Oct 26.

13.

[Methods of development of recommendations for clinical practice (RCP) and of setting-up of a platform cancer heart vessels (PTF-CHV) in the inter3C Vaucluse-Arles].

Debourdeau P, Meuleman C, Dufaitre G, Laroche JP, Slama B, Chebrek S, Aboukhoudir F, Mège A, Dotigny R, Serin D.

Bull Cancer. 2015 Nov;102(11):932-9. doi: 10.1016/j.bulcan.2015.08.002. Epub 2015 Sep 16. French.

PMID:
26386678
14.

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.

de Swart L, Smith A, Johnston TW, Haase D, Droste J, Fenaux P, Symeonidis A, Sanz G, Hellström-Lindberg E, Cermák J, Germing U, Stauder R, Georgescu O, MacKenzie M, Malcovati L, Holm MS, Almeida AM, Mądry K, Slama B, Guerci-Bresler A, Sanhes L, Beyne-Rauzy O, Luño E, Bowen D, de Witte T.

Br J Haematol. 2015 Aug;170(3):372-83. doi: 10.1111/bjh.13450. Epub 2015 Apr 24.

PMID:
25907546
15.

Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients.

Khellaf M, Charles-Nelson A, Fain O, Terriou L, Viallard JF, Cheze S, Graveleau J, Slama B, Audia S, Ebbo M, Le Guenno G, Cliquennois M, Salles G, Bonmati C, Teillet F, Galicier L, Hot A, Lambotte O, Lefrère F, Sacko S, Kengue DK, Bierling P, Roudot-Thoraval F, Michel M, Godeau B.

Blood. 2014 Nov 20;124(22):3228-36. doi: 10.1182/blood-2014-06-582346. Epub 2014 Oct 7.

16.

Dynamics of squeezing fluids: clapping wet hands.

Gart S, Chang B, Slama B, Goodnight R, Um SH, Jung S.

Phys Rev E Stat Nonlin Soft Matter Phys. 2013 Aug;88(2):023007. Epub 2013 Aug 9.

PMID:
24032924
17.

MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.

Leleu X, Rodon P, Hulin C, Daley L, Dauriac C, Hacini M, Decaux O, Eisemann JC, Fitoussi O, Lioure B, Voillat L, Slama B, Al Jijakli A, Benramdane R, Chaleteix C, Costello R, Thyss A, Mathiot C, Boyle E, Maloisel F, Stoppa AM, Kolb B, Michallet M, Lamblin A, Natta P, Facon T, Elalamy I, Fermand JP, Moreau P.

Thromb Haemost. 2013 Oct;110(4):844-51. doi: 10.1160/TH13-02-0140. Epub 2013 Aug 1.

PMID:
23903204
18.

Bragg scattering and Brownian motion dynamics in optically induced crystals of submicron particles.

Sapiro RE, Slama BN, Raithel G.

Phys Rev E Stat Nonlin Soft Matter Phys. 2013 May;87(5):052311. Epub 2013 May 29.

PMID:
23767544
19.

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.

Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Adès L, Pillard F, Lamberto C, Charniot JC, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, Ame S, Damaj G, Boyer F, Chaury MP, Legros L, Cheze S, Testu A, Gyan E, Béné MC, Rose C, Dreyfus F, Fenaux P.

Ann Hematol. 2013 May;92(5):621-31. doi: 10.1007/s00277-013-1686-4. Epub 2013 Jan 29. Erratum in: Ann Hematol. 2013 May;92(5):633. Lambert, Christine [corrected to Lamberto, C].

PMID:
23358617
20.

Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi-Boyer V, Arnoulet C, Gisserot O, Verrot D, Slama B, Vey N, Mozziconacci MJ, Birnbaum D, Murati A.

Genes Chromosomes Cancer. 2012 Aug;51(8):743-55. doi: 10.1002/gcc.21960. Epub 2012 Apr 9.

PMID:
22489043
21.

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C, Della Valle V, Couronné L, Scourzic L, Chesnais V, Guerci-Bresler A, Slama B, Beyne-Rauzy O, Schmidt-Tanguy A, Stamatoullas-Bastard A, Dreyfus F, Prébet T, de Botton S, Vey N, Morgan MA, Cross NC, Preudhomme C, Birnbaum D, Bernard OA, Fontenay M; Groupe Francophone des Myélodysplasies.

Blood. 2012 Apr 5;119(14):3211-8. doi: 10.1182/blood-2011-12-400994. Epub 2012 Feb 17.

22.

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.

Sibon D, Cannas G, Baracco F, Prebet T, Vey N, Banos A, Besson C, Corm S, Blanc M, Slama B, Perrier H, Fenaux P, Wattel E; Groupe Francophone des Myélodysplasies.

Br J Haematol. 2012 Mar;156(5):619-25. doi: 10.1111/j.1365-2141.2011.08979.x. Epub 2011 Dec 23.

PMID:
22211483
23.

Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.

Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Voillat L, Moreau P, Berthou C, Stoppa AM, Maloisel F, Rodon P, Dib M, Pegourie B, Casassus P, Slama B, Damaj G, Zerbib R, Harousseau JL, Mohty M, Facon T; Intergroupe Francophone du Myélome (IFM).

Eur J Haematol. 2012 Mar;88(3):249-59. doi: 10.1111/j.1600-0609.2011.01729.x. Epub 2012 Jan 4.

PMID:
22023551
24.

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.

Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B.

Blood. 2011 Oct 20;118(16):4338-45. doi: 10.1182/blood-2011-03-340166. Epub 2011 Aug 10.

25.

Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.

Park S, Sapena R, Kelaidi C, Vassilieff D, Bordessoule D, Stamatoullas A, Cheze S, Beyne-Rauzy O, Vey N, Rose C, Guerci A, Natarajan-Amé S, Tertian G, Slama B, Fenaux P, Dreyfus F.

Leuk Res. 2011 Nov;35(11):1530-3. doi: 10.1016/j.leukres.2011.07.007. Epub 2011 Jul 30.

PMID:
21803419
26.

Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO).

Lortholary A, Largillier R, Weber B, Gladieff L, Alexandre J, Durando X, Slama B, Dauba J, Paraiso D, Pujade-Lauraine E; GINECO group France.

Ann Oncol. 2012 Feb;23(2):346-52. doi: 10.1093/annonc/mdr149. Epub 2011 May 11.

PMID:
21562072
27.

Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level.

Legros L, Slama B, Karsenti JM, Vey N, Natarajan-Amé S, Watel E, Richard B, Bouabdallah K, Mannone L, Benchetrit M, Touitou I, Huault S, Durivault J, Ambroseti D, Hueber AO, Fenaux P, Dreyfus F; Groupe Francophone des Myélodysplasies.

Ann Hematol. 2012 Jan;91(1):39-46. doi: 10.1007/s00277-011-1242-z. Epub 2011 May 7.

PMID:
21553011
28.

[Renal failure in Tunisian patients with type 2 diabetes: frequency and related factors].

Bouzid C, Smida H, Kacem A, Turki Z, Ben Salem L, Ben Rayana C, Slama BC.

Tunis Med. 2011 Jan;89(1):10-5. French.

29.

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.

Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, Hunault-Berger M, Slama B, Vey N, Lacombe C, Solary E, Birnbaum D, Bernard OA, Fontenay M.

Leukemia. 2010 May;24(5):1094-6. doi: 10.1038/leu.2010.52. Epub 2010 Apr 8. No abstract available.

PMID:
20376084
30.

Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE.

de la Fouchardière C, Largillier R, Goubely Y, Hardy-Bessard AC, Slama B, Cretin J, Orfeuvre H, Paraiso D, Bachelot T, Pujade-Lauraine E.

Ann Oncol. 2009 Dec;20(12):1959-63. doi: 10.1093/annonc/mdp231. Epub 2009 Jun 25.

PMID:
19556321
31.

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases.

Itzykson R, Ayari S, Vassilief D, Berger E, Slama B, Vey N, Suarez F, Beyne-Rauzy O, Guerci A, Cheze S, Thomas X, Stamatoullas A, Gardembas M, Bauduer F, Kolb A, Chaury MC, Legros L, Damaj G, Chermat F, Dreyfus F, Fenaux P, Ades L; Groupe Francophone des Myelodysplasies (GFM).

Leukemia. 2009 Apr;23(4):673-8. doi: 10.1038/leu.2008.362. Epub 2009 Jan 8.

PMID:
19151787
32.

Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review.

Peyrade F, Triby C, Slama B, Fontana X, Gressin R, Broglia JM, Lepeu G, Carrier P, Peyrottes I, Darcourt J, Bondiau PY, Thyss A.

Leuk Lymphoma. 2008 Sep;49(9):1762-8. doi: 10.1080/10428190802273278. Review.

PMID:
18661403
33.

Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.

Tamburini J, Elie C, Park S, Beyne-Rauzy O, Gardembas M, Berthou C, Mahe B, Sanhes L, Stamatoullas A, Vey N, Aouba A, Slama B, Quesnel B, Vekhoff A, Sotto JJ, Vassilief D, Al-Nawakil C, Fenaux P, Dreyfus F, Bouscary D; Groupe Francophone des Myélodysplasies, GFM.

Leuk Res. 2009 Apr;33(4):547-50. doi: 10.1016/j.leukres.2008.06.005. Epub 2008 Jul 21. No abstract available.

PMID:
18640718
34.

Widespread granuloma annulare and Hodgkin's disease.

Dadban A, Slama B, Azzedine A, Lepeu G.

Clin Exp Dermatol. 2008 Jul;33(4):465-8. doi: 10.1111/j.1365-2230.2008.02730.x. Epub 2008 May 6.

PMID:
18462441
35.

Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.

Abgrall JF, Guibaud I, Bastie JN, Flesch M, Rossi JF, Lacotte-Thierry L, Boyer F, Casassus P, Slama B, Berthou C, Rodon P, Leporrier M, Villemagne B, Himberlin C, Ghomari K, Larosa F, Rollot F, Dugay J, Allard C, Maigre M, Isnard F, Zerbib R, Cauvin JM; Groupe Ouest-Est Leucémies et Maladies du Sang (GOELAMS).

Haematologica. 2006 Aug;91(8):1027-32.

36.

Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion.

Murati A, Arnoulet C, Lafage-Pochitaloff M, Adélaide J, Derré M, Slama B, Delaval B, Popovici C, Vey N, Xerri L, Mozziconacci MJ, Boulat O, Sainty D, Birnbaum D, Chaffanet M.

Int J Oncol. 2005 Jun;26(6):1485-92.

PMID:
15870860
37.

Transient myocardial perfusion abnormalities during cold provocation test in patients with arterial hyperreactivity.

Stefenelli T, Sochor H, Slama B, Czernin J, Pachinger O, Probst P.

Z Kardiol. 1991 Oct;80(10):622-6.

PMID:
1771961
38.

[Polyradiculoneuritis disclosing cancer of the lung].

M'Raihi L, Damak ML, Ouzir AL, Ben Slama B, Boukhris R.

Tunis Med. 1988 May;66(5):477-80. Review. French. No abstract available.

PMID:
3061091
39.

DH Ergotoxin (Spofa) sublingual tablets in the treatment of cerebrovascular insufficiency in involution: clinical and experimental psychologic study.

Misurec J, Morávek Z, Náhunek K, Cesková E, Sláma B, Svestka J.

Act Nerv Super (Praha). 1978 Dec;20(4):266-7. No abstract available.

PMID:
367038
40.

A controlled study of lisurid in hyperactive children.

Výborová L, Náhunek K, Drtílková I, Misurec J, Sláma B.

Act Nerv Super (Praha). 1978 Feb;20(1):86-7. No abstract available.

PMID:
345719
41.

Prophylactic lithium treatment of drug abuse.

Náhunek K, Kamenická V, Misurec J, Sláma B, Svestka J, Novotná H.

Act Nerv Super (Praha). 1978 Feb;20(1):70-2. No abstract available.

PMID:
345718
42.

[Long-term use of lithium for prevention of drug dependence].

Nagunek K, Shvestka Ia, Kamenitska V, Slama B.

Zh Nevropatol Psikhiatr Im S S Korsakova. 1977;77(8):1233-5. Russian. No abstract available.

PMID:
899540
43.
44.

The effect of a single application of lisurid (Lysenyl Spofa) in healthy volunteers.

Kamenická V, Kulísková O, Sláma B, Misurec J, Náhunek K.

Act Nerv Super (Praha). 1976;18(3):235-6. No abstract available.

PMID:
795257
45.

Proceedings: Possibilities of the prophylactic treatment of drug abuse.

Náhunek K, Sláma B, Kulísková O, Mandlová I, Misurec J.

Act Nerv Super (Praha). 1975;17(4):267-8. No abstract available.

PMID:
1221792
46.

Proceedings: Experimental and short-term clinical trials with mesylphenacyrazine.

Kulísková O, Náhunek K, Misurec J, Sláma B, Svestka J, Kamenická V.

Act Nerv Super (Praha). 1975;17(4):236-7. No abstract available.

PMID:
1221771
47.

Proceedings: Medazepam, oxazepam and placebo--clinical and experimental study.

Boleloucký Z, Náhunek K, Kamenická V, Kulísková O, Misurec J, Sláma B.

Act Nerv Super (Praha). 1975;17(4):277-8. No abstract available.

PMID:
3936
48.

[Psychic changes after hepatic coma (author's transl)].

Horecká J, Mandlová I, Misurec J, Sláma B, Jezek P.

Cesk Gastroenterol Vyz. 1973 Dec;27(8):514-20. Czech. No abstract available.

PMID:
4769623
49.

The psychotropic effect of a single dose of oxyprothepin and octoclothepin in healthy volunteers.

Náhunek K, Kamenická V, Sláma B, Misurec J, Pernica M.

Act Nerv Super (Praha). 1973 May;15(2):101. No abstract available.

PMID:
4584769

Supplemental Content

Support Center